In a recent development that may lead to increased cooperation between industry stakeholders and the US Food and Drug Administration (FDA), the agency released a draft guidance document for formal meetings with PDUFA product sponsors and applicants on September 22, 2023.
This new document, titled “Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products” (the Draft Guidance), introduces changes that could potentially improve access and interaction between the FDA and key industry players. One of the substantial changes noticed is the inclusion of two new types of formal meetings to which the FDA has shown a willingness to commit.
The FDA’s recent shift in approach as signaled by the Draft Guidance represents an important step toward encouraging more productive interactions between the agency and pharmaceutical industry stakeholders. With the FDA showing a greater willingness to engage, there is an anticipation for increased opportunities for corporations to have their voices heard during the regulatory process, which can significantly impact their success in the challenging pharmaceutical market.
This development, announced in a briefing by Latham & Watkins LLP, one of the world’s leading law firms, will likely be welcomed by many in the legal profession that deal with health care and life sciences corporations, by potentially facilitating a more efficient and effective review process.
The final impact of the Draft Guidance and the FDA’s potential for enhanced cooperation with industry remains to be seen, but legal professionals would be well-advised to keep a close eye on subsequent developments in this area.